环戊烷羧酸哌啶-4-基酰胺 | 883548-75-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 环戊烷羧酸哌啶-4-基酰胺
• 英文名称: Cyclopentanecarboxylic acid piperidin-4-ylamide
• 英文别名: N-piperidin-4-ylcyclopentanecarboxamide
• CAS: 883548-75-2
• 化学式: C₁₁H₂₀N₂O
• 分子量: 196.293
• InChiKey: WCCWHEDYTQBSPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  环戊烷羧酸哌啶-4-基酰胺 在 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 54.0h， 生成 N-(1-(1-isopropylpiperazine-4-carbonyl)piperidin-4-yl)cyclopentanecarboxamide
  参考文献：
  名称：

  Ureas with histamine H3-antagonist receptor activity—A new scaffold discovered by lead-hopping from cinnamic acid amides

  摘要：

  A group of tri and tetrasubstituted urea derivatives have been found to be hH(3)-antagonists. The most potent compounds were found in the class of (piperazine-1-yl)-(piperidine-1-yl)-methanones which in addition showed negligible hERG inhibition. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.07.093
• 作为产物：
  描述：

  tert-Butyl 4-(cyclopentanecarbonylamino)piperidine-1-carboxylate 在 三氟乙酸 作用下， 反应 2.0h， 生成 环戊烷羧酸哌啶-4-基酰胺
  参考文献：
  名称：

  Discovery of N-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): An Allosteric Muscarinic M₁ Receptor Agonist with Unprecedented Selectivity and Procognitive Potential

  摘要：

  The discovery and structure activity relationship (SAR) of a series of allosteric muscarinic M, receptor agonists are described. Compound 17 (Lu AE51090) was identified as a representative compound from the series, based on its high selectivity as an agonist at the muscarinic M-1 receptor across a panel of muscarinic receptor subtypes. Furthermore, 17 displayed a high degree of selectivity when tested in a broad panel of G-protein-coupled receptors, ion channels, transporters, and enzymes, and 17 showed an acceptable pharmacokinetic profile and sufficient brain exposure in rodents in order to characterize the compound in vivo. Hence, in a rodent model of learning and memory, 17 reversed delay-induced natural forgetting, suggesting a procognitive potential of 17.

  DOI：

  10.1021/jm100697g

文献信息

• DERIVATIVES OF BETA-AMINO ACID AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS
  申请人：RANBAXY LABORATORIES, LTD.

  公开号：EP1973918A2

  公开（公告）日：2008-10-01
• PERIPHERALLY RESTRICTED DIPHENYL PURINE DERIVATIVES
  申请人：Research Triangle Institute

  公开号：EP2814828B9

  公开（公告）日：2020-10-07
• [EN] DERIVATIVES OF BETA-AMINO ACID AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS<br/>[FR] DÉRIVÉS DE BÊTA-AMINOACIDES COMME INHIBITEURS DE LA DIPEPTIDYLPEPTIDASE IV
  申请人：RANBAXY LAB LTD

  公开号：WO2007077508A2

  公开（公告）日：2007-07-12

  [EN] The present invention relates to ß-amino acid derivatives as dipeptidyl peptidase- IV inhibitors and the processes for the synthesis of the same. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating diabetes, especially type 2 diabetes, as well as prediabetes, diabetic dyslipidemia, metabolic acidosis, ketosis, satiety disorders, and obesity. These inhibitors can also be used to treat conditions manifested by a variety of metabolic, neurological, anti-inflammatory, and autoimmune disorders like inflammatory disease, multiple sclerosis, rheumatoid arthritis; viral, cancer and gastrointestinal disorders. The compounds of this invention can also be used for treatment of infertility arising due to polycystic ovary syndrome.
  [FR] La présente invention concerne des dérivés de ß-aminoacides utilisés comme inhibiteurs de la dipeptidylpeptidase IV, ainsi que les procédés de synthèse de ces inhibiteurs. La présente invention concerne également des compositions pharmacologiques contenant les composés de la présente invention, et des procédés de traitement du diabète, notamment du diabète de type 2, ainsi que du prédiabète, de la dyslipidémie diabétique, de l'acidose métabolique, de la cétose, des troubles de la satiété et de l'obésité. Ces inhibiteurs peuvent également être utilisés pour traiter des affections qui se manifestent par divers troubles métaboliques, neurologiques, anti-inflammatoires et auto-immuns telles que la maladie inflammatoire, la sclérose en plaques, la polyarthrite rhumatoïde ; des troubles viraux, cancéreux et gastro-intestinaux. Les composés de la présente invention peuvent également être utilisés pour le traitement de l'infertilité due au syndrome de l'ovaire polykystique.